Defunct Company
Total Trials
3
As Lead Sponsor
0
As Collaborator
Total Enrollment
520
NCT04281186
Retinal and Cognitive Dysfunction in Type 2 Diabetes
Phase: N/A
Role: Collaborator
Start: Nov 16, 2020
Completion: Dec 31, 2024
NCT05762510
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
Phase: Early Phase 1
Start: Feb 22, 2023
Completion: Oct 31, 2030
NCT05757245
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
Phase: Phase 1
Start: May 8, 2023
Completion: Dec 31, 2030